Efficacy and safety of ganirelix acetate versus leuprolide acetate in women undergoing controlled ovarian hyperstimulation

This publication has 11 references indexed in Scilit:

• Pharmacokinetic and pharmacodynamic characteristics of ganirelix (Antagon/Orgalutran). part II. dose-proportionality and gonadotropin suppression after multiple doses of ganirelix in healthy female volunteers
  Fertility and Sterility, 1999
• Pharmacokinetic and pharmacodynamic characteristics of ganirelix (Antagon/Orgalutran ). part I. absolute bioavailability of 0.25 mg of ganirelix after a single subcutaneous injection in healthy female volunteers
  Fertility and Sterility, 1999
• Minimal ovarian stimulation for IVF: appraisal of potential benefits and drawbacks
  Human Reproduction, 1999
• A double-blind, randomized, dose-finding study to assess the efficacy of the gonadotrophin-releasing hormone antagonist ganirelix (Org 37462) to prevent premature luteinizing hormone surges in women undergoing ovarian stimulation with recombinant follicle stimulating hormone (Puregon). The ganirelix dose-finding study group
  Human Reproduction, 1998
• Future trends in infertility treatment: Challenges ahead
  Fertility and Sterility, 1997
• Neuropsychologic dysfunction in women following leuprolide acetate induction of hypoestrogenism
  Journal of Assisted Reproduction and Genetics, 1993
• The routine use of gonadotropin-releasing hormone agonists prior to in vitro fertilization and gamete intrafallopian transfer: a meta-analysis of randomized controlled trials
  Fertility and Sterility, 1992
• Will GNRH antagonists be worth the wait?
  Reproductive Medicine Review, 1992
• GnRH Analogues in Ovarian Stimulation
  Annals of the New York Academy of Sciences, 1991
• Gonadotropin-Releasing Hormone Analog Design. Structure-Function Studies Toward the Development of Agonists and Antagonists: Rationale and Perspective
  Endocrine Reviews, 1986